FindTrial
Sign In

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

Expanded Access Use of OFEV (Nintedanib) in Non-IPF Interstitial Lung Disease

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03843892
Enrollment
Unknown
Registered
2019-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Diseases, Interstitial

Brief summary

This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.

Interventions

DRUGOFEV

twice daily

Sponsors

Boehringer Ingelheim
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

None

Exclusion criteria

\- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation in this Expanded Access Program (EAP).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026